Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 1,838 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- C Clear all

Conditions: Healthy
Interventions: Gabapentin, Diphenhydramine citrate, Triazolam, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 4
States / cities: South Miami, Florida • Atlanta, Georgia

Conditions: Adult Primary Liver Cancer, Hepatitis C Infection
Interventions: S-adenosyl-L-methionine disulfate p-toluene-sulfonate, placebo, laboratory biomarker analysis, immunoenzyme technique, high performance liquid chromatography; Drug · Other
Lead sponsor: Chao Family Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 5
States / cities: Tucson, Arizona • Long Beach, California • Los Angeles, California + 2 more

Conditions: Bladder Cancer
Interventions: Apaziquone, Placebo; Drug · Other
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Type 2 Diabetes Mellitus
Interventions: GK1-399 (formerly TTP399), Placebo; Drug
Lead sponsor: vTv Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 11
States / cities: Little Rock, Arkansas • Chula Vista, California • DeLand, Florida + 8 more

Conditions: Covid19
Interventions: Fluticasone, Placebo; Drug · Other
Lead sponsor: Susanna Naggie, MD; Other
Eligibility: 30 Years and older
Enrollment: 1,407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 87
States / cities: Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 75 more

Conditions: Intraocular Pressure
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Functional Constipation
Interventions: Linaclotide, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Months to 23 Months
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 18
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Anaheim, California + 14 more

Conditions: Postoperative Pain
Interventions: TAP-C, TAP-S; Device · Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: HCV Infection
Interventions: GS-9450, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 51
States / cities: Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 48 more

Conditions: Alzheimer's Disease
Interventions: MEM 1003, Placebo for MEM 1003; Drug
Lead sponsor: Memory Pharmaceuticals; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 57
States / cities: Northport, Alabama • Mesa, Arizona • Phoenix, Arizona + 51 more

Conditions: Alcohol Use Disorder, Mild Traumatic Brain Injury, Post-traumatic Stress Disorder
Interventions: repetitive transcranial magnetic stimulation; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 22 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Hines, Illinois

Conditions: Hepatitis C Virus Infection
Interventions: Voxilaprevir, Placebo to match voxilaprevir, SOF/VEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 10
States / cities: Costa Mesa, California • DeLand, Florida • Orlando, Florida + 7 more

Conditions: Cervical Dystonia
Interventions: Corabotase, Placebo; Biological · Other
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: Tucson, Arizona • Fountain Valley, California • Loma Linda, California + 7 more

Conditions: Chronic Hepatitis C Infection
Interventions: VBY 376; Drug
Lead sponsor: Virobay Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Myocardial Infarction, Cardiovascular Diseases, Pathologic Processes
Interventions: KAI-9803; Drug
Lead sponsor: KAI Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 17
States / cities: Huntsville, Alabama • Escondido, California • Torrance, California + 14 more

Conditions: Cardiovascular Function in EMTs
Interventions: Antioxidant cocktail, Placebo; Dietary Supplement
Lead sponsor: University of Delaware; Other
Eligibility: 20 Years to 40 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Hepatitis, Hepatitis C
Interventions: Filibuvir, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 30
States / cities: Anaheim, California • Coronado, California • La Jolla, California + 22 more

Conditions: Hepatitis C Virus Infection
Interventions: VGX-410 (Mifepristone), Placebo; Drug
Lead sponsor: VGX Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 4
States / cities: Farmington, Connecticut • Orlando, Florida • St Louis, Missouri + 1 more

Conditions: Irritable Bowel Syndrome With Constipation
Interventions: SYN-010 21 mg, SYN-010 42 mg, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Knee-extensor exercise test, Exercise test with restricting/releasing blood flow, Exercise test with variable oxygen concentration and MRI, Exercise test with oral antioxidant or placebo cocktail; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Rosacea, Acne Vulgaris, Atopic Dermatitis, Seborrheic Dermatitis
Interventions: Topical oxygen, placebo; Drug
Lead sponsor: Aria Aesthetics Inc.; Industry
Eligibility: 25 Years to 60 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Healthy
Interventions: LY4226695, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 148 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Irritable Bowel Syndrome
Interventions: MD-1100 Acetate; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pancreatic Ductal Adenocarcinoma
Interventions: Navlimetostat, Gemcitabine, Nab-paclitaxel, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 48
States / cities: Phoenix, Arizona • Tucson, Arizona • Springdale, Arkansas + 38 more

Search by objective public record fields.

Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers

Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection

A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)

A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone)

Intraocular Pressure During Spine Surgery

A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide

Single-shot TAP Block vs Continuous TAP Block

Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection

Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

Pilot rTMS for AUD+mTBI

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults

Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults

Safety and Efficacy Study of KAI-9803 to Treat Subjects With ST Elevation Myocardial Infarction [Heart Attack]

Vascular Function and Oxidative Stress in Emergency Medical Responders

Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects

Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients

Efficacy and Safety of SYN-010 in IBS-C

Exercise in Health and Chronic Obstructive Pulmonary Disease

The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage

A Study of LY4226695 in Healthy Participants

Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS

A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)